The effect of antithyroid treatment on atrial conduction times in patients with subclinical hyperthyroidism

Alper Buğra Nacar1, Gürkan Acar, Hikmet Yorgun

  • 1Elbistan State Hospital, Kahramanmaraş, Turkey. dralpernacar@hotmail.com

Insights

Subclinical hyperthyroidism (SH) prolongs atrial conduction time, increasing atrial fibrillation risk. Antithyroid treatment normalized conduction times, suggesting a preventive role against atrial fibrillation.

Area of Science:

  • Cardiology
  • Endocrinology
  • Medical Imaging

Background:

  • Prolonged atrial conduction time is linked to increased atrial fibrillation risk.
  • Subclinical hyperthyroidism (SH) may affect atrial electrophysiology.
  • Tissue Doppler imaging (TDI) measures atrial conduction time.

Purpose of the Study:

  • To assess the impact of SH on atrial conduction time.
  • To evaluate the effect of antithyroid treatment on atrial conduction in SH patients.

Main Methods:

  • 30 SH patients and 30 controls underwent TDI measurements of atrial conduction.
  • Intra- and interatrial conduction delays were calculated.
  • Measurements were taken at baseline and after achieving euthyroid state with propylthiouracil.

Main Results:

  • SH patients exhibited significantly prolonged atrial conduction times compared to controls.
  • Interatrial, right, and left intraatrial electromechanical delays were longer in SH patients.
  • Antithyroid treatment normalized these delays, bringing them closer to control values.

Conclusions:

  • Subclinical hyperthyroidism is associated with prolonged atrial conduction.
  • Normalization of conduction times after treatment suggests a potential mechanism for preventing atrial fibrillation in SH patients.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...